Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: In the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Timing trial, Dr Stone and colleagues1 reported that more than 10% of patients developed thrombocytopenia, defined as a platelet count of less than 150 000/μL. Prior studies have defined thrombocytopenia as either less than 100 000/μL or at least a 25% decrease from baseline, with incidence ranging from 0.5% to 5.6%.2,3 It is unclear how many patients in the ACUITY trial developed significant thrombocytopenia using these alternative definitions.
Naina HVK, Harris S, Singla A. Timing of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. JAMA. 2007;298(1):37–38. doi:10.1001/jama.298.1.37-a
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: